SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24" > Health-related qual...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005781naa a2200661 4500
001oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24
003SwePub
008201222s2020 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/78f8c9e1-3b92-4677-a542-20c86d4eec242 URI
0247 a https://doi.org/10.3324/haematol.2019.2222992 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Nielsen, Lene Kongsgaardu Odense University Hospital4 aut
2451 0a Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
264 c 2019-09-12
264 1b Ferrata Storti Foundation (Haematologica),c 2020
300 a 10 s.
520 a Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size. In general, improvement occurred after 6-12 months of maintenance only and was independent of the World Health Organisation performance at baseline. Patients treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for at least three months reported clinically meaningful improvement in global QoL and role functioning at six months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on thalidomide reported clinically relevant worsening in neuropathy. In general, HRQoL improves both during induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did not negatively affect global QoL, but it was, however, clinically relevant for the patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Stege, Claudiau Vrije Universiteit Amsterdam4 aut
7001 a Lissenberg-Witte, Birgitu Vrije Universiteit Amsterdam4 aut
7001 a Der Holt, Bronno Vanu Erasmus University Medical Center4 aut
7001 a Mellqvist, Ulf Henriku Sahlgrenska University Hospital4 aut
7001 a Salomo, Mortenu Copenhagen University Hospital4 aut
7001 a Bos, Gerardu Yukioka Hospital4 aut
7001 a Levin, Mark David4 aut
7001 a Visser-Wisselaar, Heleenu Erasmus University Medical Center4 aut
7001 a Hansson, Markusu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Myelomgruppen,Forskargrupper vid Lunds universitet,WCMM- Wallenberg center för molekylär medicinsk forskning,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Myeloma research group,Lund University Research Groups,WCMM-Wallenberg Centre for Molecular Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)hema-mha
7001 a Der Velden, Annette Vanu Martini Hospital, Groningen4 aut
7001 a Deenik, Wendy4 aut
7001 a Coenen, Juleonu Maastricht University Medical Centre4 aut
7001 a Hinge, Majau Vejle Hospital4 aut
7001 a Klein, Saskiau Meander Medical Center4 aut
7001 a Tanis, Bea4 aut
7001 a Szatkowski, Damian4 aut
7001 a Brouwer, Rolfu Reinier de Graaf Hospital - SSDZ4 aut
7001 a Westerman, Matthijs4 aut
7001 a Leys, Rineke4 aut
7001 a Sinnige, Harmu Jeroen Bosch Hospital4 aut
7001 a Haukås, Einaru Stavanger University Hospital4 aut
7001 a Der Hem, Klaas Van4 aut
7001 a Durian, Marc4 aut
7001 a Gimsing, Peteru Copenhagen University Hospital4 aut
7001 a De Donk, Niels Vanu Vrije Universiteit Amsterdam4 aut
7001 a Sonneveld, Pieteru Erasmus University Medical Center4 aut
7001 a Waage, Andersu St. Olav’s University Hospital4 aut
7001 a Abildgaard, Nielsu Odense University Hospital4 aut
7001 a Zweegman, Sonjau Vrije Universiteit Amsterdam4 aut
7102 a Odense University Hospitalb Vrije Universiteit Amsterdam4 org
7730 t Haematologicad : Ferrata Storti Foundation (Haematologica)g 105:6, s. 1650-1659q 105:6<1650-1659x 0390-6078x 1592-8721
8564 u http://dx.doi.org/10.3324/haematol.2019.222299x freey FULLTEXT
8564 u https://haematologica.org/article/download/9441/69046
8564 8u https://lup.lub.lu.se/record/78f8c9e1-3b92-4677-a542-20c86d4eec24
8564 8u https://doi.org/10.3324/haematol.2019.222299

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy